Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315433 | 0.85 | SMYD3 (0.30) | — | |
| SCHEMBL7216627 | 0.85 | CA1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL24176238 | 0.81 | PKM (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL2257967 | 0.74 | — | — | |
| SCHEMBL9155653 | 0.74 | — | — | |
| SCHEMBL2476446 | 0.73 | CA1 (0.33) | CA1CA2CA4CA9 | |
| SCHEMBL2721926 | 0.73 | CA1 (0.45) | CA1CA2CA4CA9 | |
| SCHEMBL3611388 | 0.72 | CA1 (0.43) | CA1CA2CA4CA9 | |
| SCHEMBL27551532 | 0.72 | — | — | |
| SCHEMBL16321917 | 0.72 | CA1 (0.44) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109562059-A | Formulations for administration of RNA | 生物技术RNA制药有限公司 | 2019-04-02 | — | — | CN | claimed |
| WO-2025237916-A1 | BIOMATERIAL COMPOSITION COMPRISING A POLYHYDROXYBUTYRATE IN PARTICULATE FORM | LABORATOIRES VIVACY (FR) | 2025-11-20 | — | — | WO | disclosed |
| CN-118027190-A | TRPM3 antibody, and preparation method and application thereof | 深圳晶蛋生物医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-116693682-B | Anti-Tau protein antibody, preparation method and application thereof | 涌源合生科技(深圳)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4244610-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | Nanjing University (CN) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023056960-A1 | SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE | NANJING UNIVERSITY (CN) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022100147-A1 | PROGRAMMABLE NANO-REACTORS FOR STOCHASTIC SENSING (PNRSS) | NANJING UNIVERSITY (CN) | 2022-05-19 | — | — | WO | disclosed |
| EP-3829535-A1 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CUTANEOUS AFFECTIONS | I.C.F. S.r.l. (IT) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021036995-A1 | DIRECT MICRORNA SEQUENCING USING ENZYME ASSISTED SEQUENCING | NANJING UNIVERSITY (CN) | 2021-03-04 | — | — | WO | disclosed |
| WO-2019041340-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-108948135-A | Cell cycle protein dependent kinase substrate | 希森美康株式会社 | 2018-12-07 | — | — | CN | disclosed |
| CN-103958468-B | Piperidinylnaphthylacetic acids | 弗·哈夫曼-拉罗切有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-103804991-B | Ink jet recording method and record thing | 精工爱普生株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-20120258961-A1 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-5958907-A | Pharmaceutical compositions and uses of inorganic pyrophosphates | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1999-09-28 | — | — | US | disclosed |
| US-5830741-A | RAPID RECOVERY OF VIABLE CELLS | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| US-5753485-A | Purified mixture of collagenase I, collagenase II and two other proteases | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5686114-A | Uses of inorganic pyrophosphates | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1996006639-A2 | NOVEL DRUGS CONTAINING CHELATE-FORMING AGENTS | MEDICO PHARMA VERTRIEBS GMBH (DE) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258961-A1 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE | APP, IAPP, APBA1 | CA1 817/4885CA2 886/4885CA4 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.